10080 N WOLFE ROAD, CUPERTINO, CA
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Material disclosure
Reg. FD, Other Events
Earnings Release
Announces Pricing of $10 Million Public Offering
News, Articles of Incorporation
Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Late Filing for Annual Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notification Filed by a National Security Exchange
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership